Atara reports expanded access protocol data of tabelecleucel

Atara Biotherapeutics Inc. (NASDAQ:ATRA) reported data from a U.S. expanded access protocol study showing that IV tabelecleucel led to an objective response rate (ORR) of 83% among six patients with Rituxan rituximab-refractory Epstein-Barr virus (EBV) associated post-transplant lymphoproliferative disorder (EBV-PTLD) following solid organ transplant. In five evaluable patients with EBV-PTLD following allogeneic hematopoietic cell transplant (HCT), tabelecleucel led to an ORR of 80%. A sixth patient with EBV-PTLD following HCT remains alive, but was not evaluable due to lack of post-baseline assessment.

The estimated one-year overall survival (OS) rate among all 12 EBV-PTLD patients following solid organ transplant or HCT was 90.9%...